Compounding pharmacies make their own versions of weight loss drugs at a fraction of the price but there are some drawbacks.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Top stocks for 2025 are from the companies that have proven growth track records and strong outlooks, with more potential ...

Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...

The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...